Psoriasis
Conditions
Keywords
Psoriasis, Squamous Cell Carcinoma Antigen, SCCA, Biomarker
Brief summary
Squamous Cell Carcinoma Antigen (SCCA) contributes to the pathogenesis of psoriasis by inhibiting cell apoptosis, exacerbating epidermal hyperplasia and skin inflammation. Three studies have shown a correlation between blood levels of SCCA and the severity of psoriasis. Clinical scores of psoriasis severity are used in consultation to guide treatment of the disease (initiation of systemic therapy, dose escalation) but they suffer from several pitfalls: lack of inter- and intra-observer reproducibility, consumption of medical time. A readily available, inexpensive (24 euros) blood marker could be an interesting alternative to these clinical scores.
Detailed description
Squamous Cell Carcinoma Antigen (SCCA) contributes to the pathogenesis of psoriasis by inhibiting cell apoptosis, exacerbating epidermal hyperplasia and skin inflammation. Three studies have shown a correlation between blood levels of SCCA and the severity of psoriasis. Clinical scores of psoriasis severity are used in consultation to guide treatment of the disease (initiation of systemic therapy, dose escalation). The PASI (Psoriasis Assessment Severity Index, minimum score 0, maximum 72) is the most widely used. It suffers from several pitfalls: lack of inter- and intra-observer reproducibility, consumption of medical time. This PASI score was unavoidable in the international clinical studies used to obtain marketing authorisation for medicines. The PGA (Physician global assessment) is simpler and less time-consuming, ranging from 0 to 4, but is not very discriminating. More recently, a Simplified Psoriasis Index (proSPI) health professional score has been developed, which correlates well with PASI for the severity component of psoriasis and with quality of life for the psychological component of the disease. It is less time-consuming to establish than PASI, but suffers like all clinical scores from a problem of inter- and intra-observer reproducibility. A readily available, inexpensive (24 euros) blood marker could be an interesting alternative to these clinical scores.
Interventions
OTHERBlood samples
Blood samples
Sponsors
University Hospital, Tours
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years old * Patient with skin psoriasis (new and untreated or being treated, flare-up or stable, possibly bleached) * Requiring a blood sample for disease or treatment monitoring
Exclusion criteria
* History of invasive mucosal squamous cell carcinoma, or squamous cell carcinoma of the skin with lymph node or visceral recurrence. * Patient under guardianship or curatorship * Opposition to participation in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SCCA blood concentration | Baseline, 3 months and 6 months | SCCA blood concentration will be measured at each visit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assess correlations between SCCA blood concentration and proSPI severity score | Baseline, 3 months and 6 months | proSPI severity score (0-50) will be evaluated at each visit |
| Assess correlations between SCCA blood concentration and proSPI psychosocial score | Baseline, 3 months and 6 months | proSPI psychosocial score (0-10) will be evaluated at each visit |
| Assess correlations between SCCA blood concentration and proSPI treatment score | Baseline, 3 months and 6 months | proSPI treatment score (0-10) will be evaluated at each visit |
| Assess correlations between SCCA blood concentration and C reactive protein (CRP) | Baseline, 3 months and 6 months | CRP will be measured at each visit |
| Assess correlations between SCCA blood concentration and neutrophil/lymphocyte ratio | Baseline, 3 months and 6 months | neutrophil/lymphocyte ratio will be measured at each visit |
Countries
France
Outcome results
None listed